Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2023.
Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs
{"title":"Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2023.","authors":"Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs","doi":"10.33321/cdi.2025.49.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2023 to 31 December 2023, a total of 57 hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). The 2023 survey tested 10,453 isolates, comprising <i>Enterobacterales</i> (9,503; 90.9%), <i>P. aeruginosa</i> (806; 7.7%) and <i>Acinetobacter</i> species (144; 1.4%), using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2024). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 12.9% of <i>Escherichia coli</i> and in 6.9% of <i>Klebsiella pneumoniae</i> complex isolates. Resistance rates to ciprofloxacin were 14.5% for <i>E. coli</i>; 7.8% for the <i>K. pneumoniae</i> complex; 3.2% for the <i>Enterobacter cloacae</i> complex; and 7.6% for <i>P. aeruginosa</i>. Resistance rates to piperacillin-tazobactam were 6.0%; 9.4%; 23.3%; and 13.7% for the same four species/complexes, respectively. Thirty <i>Enterobacterales</i> isolates from 30 patients were shown to harbour a carbapenemase gene: ten with a <i>bla</i><sub>NDM</sub> gene (<i>bla</i><sub>NDM-1</sub> [4], <i>bla</i><sub>NDM-5</sub> [4], <i>bla</i><sub>NDM-7</sub> [2]); nine with a <i>bla</i><sub>OXA-48</sub>-like gene (<i>bla</i><sub>OXA-244</sub> [4], <i>bla</i><sub>OXA-48</sub> [2], <i>bla</i><sub>OXA-181</sub> [1], <i>bla</i><sub>OXA-232</sub> [1], <i>bla</i><sub>OXA-484</sub> [1]); eight with <i>bla</i><sub>IMP-4</sub>; two with <i>bla</i><sub>NDM-5</sub> + a <i>bla</i><sub>OXA-181</sub>-like gene; and one with <i>bla</i><sub>KPC-2</sub> + <i>bla</i><sub>NDM-5</sub> + <i>bla</i><sub>OXA-181</sub>. Transmissible carbapenemase genes were also detected in two <i>Acinetobacter baumannii</i> complex isolates (<i>bla</i><sub>OXA-23</sub>; <i>bla</i><sub>OXA-23</sub> + <i>bla</i><sub>OXA-58</sub> + <i>bla</i><sub>IMP-4</sub>) and one <i>P. aeruginosa</i> (<i>bla</i><sub>IMP-4</sub>).</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence (2018)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2025.49.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2023 to 31 December 2023, a total of 57 hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). The 2023 survey tested 10,453 isolates, comprising Enterobacterales (9,503; 90.9%), P. aeruginosa (806; 7.7%) and Acinetobacter species (144; 1.4%), using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2024). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 12.9% of Escherichia coli and in 6.9% of Klebsiella pneumoniae complex isolates. Resistance rates to ciprofloxacin were 14.5% for E. coli; 7.8% for the K. pneumoniae complex; 3.2% for the Enterobacter cloacae complex; and 7.6% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 6.0%; 9.4%; 23.3%; and 13.7% for the same four species/complexes, respectively. Thirty Enterobacterales isolates from 30 patients were shown to harbour a carbapenemase gene: ten with a blaNDM gene (blaNDM-1 [4], blaNDM-5 [4], blaNDM-7 [2]); nine with a blaOXA-48-like gene (blaOXA-244 [4], blaOXA-48 [2], blaOXA-181 [1], blaOXA-232 [1], blaOXA-484 [1]); eight with blaIMP-4; two with blaNDM-5 + a blaOXA-181-like gene; and one with blaKPC-2 + blaNDM-5 + blaOXA-181. Transmissible carbapenemase genes were also detected in two Acinetobacter baumannii complex isolates (blaOXA-23; blaOXA-23 + blaOXA-58 + blaIMP-4) and one P. aeruginosa (blaIMP-4).